Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China

IMPORTANCE: Both pembrolizumab and sintilimab have been approved by the Chinese State Drug Administration (NMPA) for the first-line treatment of patients with advanced squamous lung cancer. The differences of the two drugs in efficacy and safety are unclear. OBJECTIVES: To compare the real-world eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wenyu, Li, Tao, Bai, Yibing, Long, Yaping, Gao, Ming, Wang, Ting, Jing, Fangfang, Zhang, Fan, Tao, Haitao, Ma, Junxun, Wang, Lijie, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130366/
https://www.ncbi.nlm.nih.gov/pubmed/37124534
http://dx.doi.org/10.3389/fonc.2023.1147903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130366/
https://www.ncbi.nlm.nih.gov/pubmed/37124534
http://dx.doi.org/10.3389/fonc.2023.1147903

Ejemplares similares